IgG/IgA titer levels of anti-S protein antibodies after vaccination for SARS-CoV-2. (A-B) IgG titer levels of anti-S protein antibodies in patients with BCL (log10 scale) vaccinated at different time points from the last B-cell–directed therapy. IgG response (A); IgA response (B). (C) Response to the vaccine (IgG titer levels) in patients with BCL receiving active treatment or within 9 months of concluding B-cell–directed treatment vs those treated more than 9 months before the vaccination vs patients with BCL who were under observation or receiving other treatments vs nursing home residents and HCP. (D) IgG titer levels in patients with BCL receiving active treatment or within 9 months from the end of active treatment vs patients under observation or who underwent treatment >9 months before vaccination. The category other includes CHOEP (cyclophosphamide-doxorubicin-vincristine-etoposide-prednisone), ICE (ifosfamide-carboplatin-etoposide), brentuximab vedotin, bexarotene, daratumumab, radiotherapy, or mogamulizumab). Patients undergoing autologous stem cell transplant or CAR T-cell therapy after induction were added to the anti-CD20+chemotherapy category. COI ≥1.0 shows positivity for SARS-CoV-2 IgG antibodies. BTKi, Bruton tyrosine kinase; Tx, treatment.